November 30, 2023
The Globe and Mail | AbCellera cuts 10 per cent of staff as biotech slump hits Vancouver antibody developer
David Martin, Managing Director and Head of Bloom Burton Equity Research comments in The Globe and Mail regarding the recent news from AbCellera (NASDAQ: ABCL).
